Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

Jaiyesimi, 1995, Use of tamoxifen for breast cancer, J. Clin. Oncol., 13, 513, 10.1200/JCO.1995.13.2.513 Ellis, 2000, Treatment of metastatic breast cancer, 749 Kuerer, 2001, Biologic basis and evolving role or aromatase inhibitors in the management of invasive carcinoma of the breast, J. Surg. Oncol., 77, 139, 10.1002/jso.1085 Wakeling, 1991, A potent specific pure antiestrogen with clinical potential, Cancer Res., 51, 3867 Osborne, 1994, The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth, Cancer Chemother. Pharmacol., 34, 89, 10.1007/BF00685924 Osborne, 1995, Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer, J. Natl. Cancer Inst., 87, 746, 10.1093/jnci/87.10.746 Howell, 2002, Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment, J. Clin. Oncol., 20, 3396, 10.1200/JCO.2002.10.057 Osborne, 2002, Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy, J. Clin. Oncol., 20, 3386, 10.1200/JCO.2002.10.058 Howell A, Osborne CK, Robertson JFR, et al. ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women—prospective combined analysis of two multicenter trials. Abstract presented at ECCO 2001, Lisbon, Portugal. Robertson, 2000, A comparison of the single-dose pharmacokinetics of ICI 182,780 (‘Faslodex’) 250 mg when given as either a one × 5-ml intramuscular injection or two × 2.5-ml injections in postmenopausal women with advanced breast cancer, Breast Cancer Res. Treat., 64, 53